Nov 27, 2023 6:05pm EST CohBar, Inc.: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (Form 8-K)
Jun 05, 2023 8:05am EDT Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
May 30, 2023 8:05am EDT Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2023 7:30am EDT CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy
Nov 08, 2022 4:03pm EST CohBar Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress
Oct 26, 2022 9:00am EDT CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022
Sep 06, 2022 9:00am EDT CohBar to Present at H.C. Wainwright 24th Annual Global Investment Conference
Aug 15, 2022 4:02pm EDT CohBar Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress